224 related articles for article (PubMed ID: 21986558)
1. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.
Eichholz A; Ferraldeschi R; Attard G; de Bono JS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):68-75. PubMed ID: 21986558
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
3. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD; Taplin ME
Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
[TBL] [Abstract][Full Text] [Related]
4. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
7. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
8. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
Zhu H; Garcia JA
Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
10. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Ang JE; Olmos D; de Bono JS
Br J Cancer; 2009 Mar; 100(5):671-5. PubMed ID: 19223900
[TBL] [Abstract][Full Text] [Related]
11. Targeting CYP17: established and novel approaches in prostate cancer.
Yap TA; Carden CP; Attard G; de Bono JS
Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
[TBL] [Abstract][Full Text] [Related]
12. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
Pal SK; Twardowski P; Josephson DY
Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
14. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN; Goodin S; Dipaola RS
Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
[TBL] [Abstract][Full Text] [Related]
16. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
17. Targeting continued androgen receptor signaling in prostate cancer.
Massard C; Fizazi K
Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
[TBL] [Abstract][Full Text] [Related]
18. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Miller M; Kunkler R
Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
[TBL] [Abstract][Full Text] [Related]
19. Beyond castration-defining future directions in the hormonal treatment of prostate cancer.
Niraula S; Chi K; Joshua AM
Horm Cancer; 2012 Apr; 3(1-2):3-13. PubMed ID: 22124843
[TBL] [Abstract][Full Text] [Related]
20. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]